Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.
نویسندگان
چکیده
منابع مشابه
[Histrelin acetate--the first once yearly LHRH agonist].
Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leu...
متن کاملRaloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density
OBJECTIVES To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration. METHODS Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4 weeks, for 48 weeks. Bone mineral density (BMD) was evaluated at admission, and after 12 treatment...
متن کاملAmenorrhoea in women with non-alcoholic chronic liver disease.
Amenorrhoea is common in women with non-alcoholic chronic liver disease, but little is known about its causes or consequences. We investigated 12 young women with non-alcoholic chronic liver disease and amenorrhoea and compared them with 11 healthy age matched controls studied in the follicular phase of the menstrual cycle. None of the patients had raised serum concentrations of follicle stimul...
متن کاملE16. Amenorrhoea, aromatase inhibitors, tamoxifen or a combination in premenopausal women
The ovary is the major site of oestrogen production in premenopausal women. Removal of the ovaries in premenopausal patients with breast cancer has long been recognised to potentially alter the course of disease. This procedure leads to a marked reduction in the circulating levels of oestrogen. It has been shown that ovariectomy given as an adjuvant treatment reduces the odds of recurrence or d...
متن کاملIntranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.
An agonist analogue of luteinising hormone releasing hormone (buserelin) was successfully used to treat women with endometriosis. A dose of 200 micrograms administered intranasally thrice daily was found to be effective in five patients, in whom the endometriotic lesions resolved after six months' treatment. Failure occurred in a sixth patient, who received only 400 micrograms once daily. Anovu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- British medical journal
دوره 294 6586 شماره
صفحات -
تاریخ انتشار 1987